News and Media

Latest News Release

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...


Company News

Cardinal Health Extends Radiopharmaceutical Manufacturing Network, Launching Second Cyclotron in Tennessee

Company Helps Support Growth of Molecular Imaging in Southeastern United States by Managing Cyclotron Facility for ProVision Healthcare in Knoxville

KNOXVILLE, Tenn., August 12, 2010 — Cardinal Health today announced an agreement with ProVision Healthcare to manage and operate its cyclotron facility in Knoxville, Tenn. The agreement will enable Cardinal Health to further expand its nationwide capability to manufacture molecular imaging biomarkers that aid in the early diagnosis, monitoring and treatment of cancer, neurological disorders and heart disease.

Cyclotrons are critical to the manufacturing process for Positron Emission Tomography (PET) molecular imaging agents, one of the fastest-growing areas of nuclear medicine. When injected into the body, these specialized radiopharmaceuticals, called biomarkers, detect and trace abnormal cellular functions that are associated with a variety of diseases. Visible using sophisticated imaging scanners, these biomarkers make it easier for physicians to non-invasively diagnose critical, life-threatening diseases in their earliest stages. They can also improve physicians’ ability to track the effectiveness of patient treatment plans.

The Knoxville cyclotron facility will mark Cardinal Health’s second in Tennessee, where the company also owns and operates a cyclotron center in Memphis. The Knoxville cyclotron facility is part of the East Tennessee Healthcare Center (ETHC), which offers a full array of clinical services including diagnostic imaging, a breast care facility and wellness, oncology and cardiology services. The cyclotron is also located nearby Cardinal Health’s existing nuclear pharmacy in Knoxville, where Cardinal Health will dispense PET imaging agents into patient-specific doses.

“ProVision Healthcare shares our commitment to quality and to making molecular imaging technology more accessible to clinicians and patients,” said John Rademacher, president of Cardinal Health’s Nuclear and Pharmacy Services. “Our agreement will play a key role in enabling us to bring this important modality to patients in Tennessee and throughout the southeast United States.”

Rademacher said that, as with all Cardinal Health operated cyclotrons, the Knoxville cyclotron facility will also be available to support clinical trials to evaluate the effectiveness of new PET imaging agents.

“Cardinal Health’s expertise in the manufacture and distribution of PET biomarkers; its expansive, national radiopharmacy network and its innovative work with pharmaceutical manufacturers to support clinical trials all made them the ideal partner to operate our cyclotron,” said Terry Douglass, founder of ProVision Healthcare. “We look forward to working with Cardinal Health to bring molecular imaging technology to the area to better meet the health care needs of our patients.” 

Cardinal Health’s Nuclear Pharmacy Services business operates the nation’s largest network of radiopharmacies. The company has strategically located its nationwide network of cyclotrons to enable nearly 100 of its 160 radiopharmacies to compound and dispense high-energy PET imaging agents in unit-dose form. The company’s vast network of “PET-enabled” pharmacies, combined with its broad nuclear pharmacy scale, comprehensive fleet and logistics capabilities enable it to play a critical role in supporting clinical trials of both proprietary and non-proprietary imaging agents.

About ProVision Healthcare
ProVision Healthcare, LLC is the principal healthcare umbrella organization of the ProVision Group of organizations. ProVision Healthcare is committed to improving patient care and outcomes through provider, physician, and community alignment in collaborative, cooperative and shared healthcare enterprises. Emphasis is placed on predictive, preventative and personalized healthcare and advanced diagnostic and therapy management solutions.  Assets and proceeds coming to ProVision Healthcare entities are returned to the community in the form of financial contributions and additional healthcare initiatives. Learn more at

About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $96 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products to more than 60,000 locations each day. The company is also a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #17 on the Fortune 500, Cardinal Health employs more than 30,000 people worldwide. More information about the company may be found at

More Company News

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...


By Victor Crawford, Chief Executive Officer of the Pharmaceutical segment at Cardinal Health


Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve...


Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will...

View all company news »

* Required Fields